FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010052029> ?p ?o ?g. }

• W2010052029 abstract "Background: Recently the FDA has withdrawn the indication for bevacizumab in metastatic breast cancer after several clinical studies failed to demonstrate an overall survival benefit. These studies however did report an increase in response rates to chemotherapy and improvement in progression free survival, suggesting a pattern of response to the drug followed by the development of resistance. We have little knowledge of the molecular mechanisms driving the development of resistance to bevacizumab. To better understand these mechanisms, we have conducted a window of opportunity study using a single cycle of bevacizumab with detailed pharmacodynamic assessments using gene expression arrays and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Methods: After ethical approval, 47 newly diagnosed locally advanced breast cancer patients were prospectively enrolled in this trial. Patients received single dose bevacizumab (15mg/ kg) 2 weeks prior to neoadjuvant chemotherapy and underwent core biopsies for gene expression and immunohistochemistry analysis and DCE-MRI scans before and 2 weeks after bevacizumab. 35 patients who had invasive ductal carcinoma together with good quality MRI scans and core biopsies before and after bevacizumab were included in this analysis. Pharmacokinetic (PK) modelling techniques were used to quantify PK parameters (K trans , k ep , v e ) from the DCE-MRI data. Gene expression profiling was performed using the Affymetrix Human Exon 1.0 ST arrays. Results: The majority of patients (28/35) showed a significant reduction in vessel permeability and blood flow of at least 30% following bevacizumab, with a mean decrease in the forward transfer constant (P k ep (P Discussion: This study highlights that the combination of DCE-MRI and gene expression arrays can lead to an improved understanding of the molecular mechanisms governing response and resistance to anti-angiogenic therapy. Heterogeneity of response to bevacizumab was demonstrated, with some tumours showing increases or no change in K trans and others marked reductions, which may be of value in early stratification for therapy maintenance. Furthermore, the gene expression analysis showed activation of pathways, which could contribute to the development of resistance. For example, we observed significant up regulation of genes involved in regulating the switch from mitochondrial metabolism to glycolysis, such as PDK1. This suggests that using bevacizumab with the other targeted agents such as Dichloroacetate, a PDK1 inhibitor might be helpful in overcoming the development of resistance and ultimately lead to improved patient survival. Our preclinical studies strongly support this possibility. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-06-01." @default.
• W2010052029 created "2016-06-24" @default.
• W2010052029 creator A5020293455 @default.
• W2010052029 creator A5035568586 @default.
• W2010052029 creator A5039560656 @default.
• W2010052029 creator A5042945442 @default.
• W2010052029 creator A5054850291 @default.
• W2010052029 creator A5061531399 @default.
• W2010052029 creator A5062601903 @default.
• W2010052029 creator A5070036061 @default.
• W2010052029 creator A5075828750 @default.
• W2010052029 creator A5076534231 @default.
• W2010052029 creator A5079633934 @default.
• W2010052029 date "2012-12-15" @default.
• W2010052029 modified "2023-09-25" @default.
• W2010052029 title "Abstract P1-06-01: Upregulation of metabolism as a potential resistance mechanism to bevacizumab in primary breast cancer" @default.
• W2010052029 doi "https://doi.org/10.1158/0008-5472.sabcs12-p1-06-01" @default.
• W2010052029 hasPublicationYear "2012" @default.
• W2010052029 type Work @default.
• W2010052029 sameAs 2010052029 @default.
• W2010052029 citedByCount "0" @default.
• W2010052029 crossrefType "proceedings-article" @default.
• W2010052029 hasAuthorship W2010052029A5020293455 @default.
• W2010052029 hasAuthorship W2010052029A5035568586 @default.
• W2010052029 hasAuthorship W2010052029A5039560656 @default.
• W2010052029 hasAuthorship W2010052029A5042945442 @default.
• W2010052029 hasAuthorship W2010052029A5054850291 @default.
• W2010052029 hasAuthorship W2010052029A5061531399 @default.
• W2010052029 hasAuthorship W2010052029A5062601903 @default.
• W2010052029 hasAuthorship W2010052029A5070036061 @default.
• W2010052029 hasAuthorship W2010052029A5075828750 @default.
• W2010052029 hasAuthorship W2010052029A5076534231 @default.
• W2010052029 hasAuthorship W2010052029A5079633934 @default.
• W2010052029 hasConcept C121608353 @default.
• W2010052029 hasConcept C126322002 @default.
• W2010052029 hasConcept C142724271 @default.
• W2010052029 hasConcept C143998085 @default.
• W2010052029 hasConcept C204232928 @default.
• W2010052029 hasConcept C2776694085 @default.
• W2010052029 hasConcept C2777802072 @default.
• W2010052029 hasConcept C530470458 @default.
• W2010052029 hasConcept C71924100 @default.
• W2010052029 hasConceptScore W2010052029C121608353 @default.
• W2010052029 hasConceptScore W2010052029C126322002 @default.
• W2010052029 hasConceptScore W2010052029C142724271 @default.
• W2010052029 hasConceptScore W2010052029C143998085 @default.
• W2010052029 hasConceptScore W2010052029C204232928 @default.
• W2010052029 hasConceptScore W2010052029C2776694085 @default.
• W2010052029 hasConceptScore W2010052029C2777802072 @default.
• W2010052029 hasConceptScore W2010052029C530470458 @default.
• W2010052029 hasConceptScore W2010052029C71924100 @default.
• W2010052029 hasLocation W20100520291 @default.
• W2010052029 hasOpenAccess W2010052029 @default.
• W2010052029 hasPrimaryLocation W20100520291 @default.
• W2010052029 hasRelatedWork W1664223940 @default.
• W2010052029 hasRelatedWork W1745550286 @default.
• W2010052029 hasRelatedWork W1994013015 @default.
• W2010052029 hasRelatedWork W2040446598 @default.
• W2010052029 hasRelatedWork W2061774102 @default.
• W2010052029 hasRelatedWork W2085143940 @default.
• W2010052029 hasRelatedWork W2116978375 @default.
• W2010052029 hasRelatedWork W2123468136 @default.
• W2010052029 hasRelatedWork W2224265073 @default.
• W2010052029 hasRelatedWork W2299661680 @default.
• W2010052029 hasRelatedWork W2324561362 @default.
• W2010052029 hasRelatedWork W2544885009 @default.
• W2010052029 hasRelatedWork W2581547394 @default.
• W2010052029 hasRelatedWork W2586361288 @default.
• W2010052029 hasRelatedWork W2599879112 @default.
• W2010052029 hasRelatedWork W2944662937 @default.
• W2010052029 hasRelatedWork W3036865115 @default.
• W2010052029 hasRelatedWork W3194092788 @default.
• W2010052029 hasRelatedWork W3203395331 @default.
• W2010052029 hasRelatedWork W3205110193 @default.
• W2010052029 isParatext "false" @default.
• W2010052029 isRetracted "false" @default.
• W2010052029 magId "2010052029" @default.
• W2010052029 workType "article" @default.